Money Midnight is currently seeking to expand our team of contributors. 1 source for smarter, safer, more profitable investing. Geneva, Switzerland, September 15, 2020 - RELIEF THERAPEUTICS HoldingSA (SIX: RLF, OTCQB: RLFTF) ("Relief" or the "Company "), a biopharmaceutical company with its lead compound RLF-100 (aviptadil) in advanced clinical development to treat severe COVID-19 patients, today announced its results for the half year ended June 30, 2020.. Operative Highlights Year to Date 2020: As…. The trial of inhalation-administered RLF-100 is slated to begin enrollment within the coming weeks. Regeneron (REGN) and Relief Therapeutics (OTC:RLFTF) can quickly reduce COVID-19. In August 2019, divestment of Relief Therapeutics SA to Sonnet BioTherapeutics Inc., an oncology-focused biotechnology company, has been agreed upon and became effective in March 2020. CONTACT:RELIEF THERAPEUTICS Holding AGRaghuram (Ram) Selvaraju, Ph.D., MBAChairman of the Board Mail: This email address is being protected from spambots. It continues to rise up the charts and emerge. RELIEF THERAPEUTICS Holding AG is listed on the SIX Swiss Exchange under the symbol RLF and quoted in the U.S. on OTCQB under the symbol RLFTF. Top-line data from this trial are expected at the end of January or early February of this year. var path = 'hr' + 'ef' + '='; You need JavaScript enabled to view it. RLF-100/Aviptadil is currently tackling ARDS in COVID-19 patients. Sep 28, 2020 • • 1 minute read. ABOUT ADVITA LIFESCIENCE GMBH AdVita Lifescience GmbH was founded in 2019 with the purpose of developing effective products and … According to the interview with Dr. Javitt the term sheet has already been signed, big banks are already doing their due … NeuroRx a company who is partnered with promising COVID-19 therapeutic maker Relief Therapeutics (OTC: RLFTF) has decided to merge and list with a NYSE company (3-6 months). var addy_textd15ff14d23b491175408c179e001a7b6 = 'relief' + '@' + 'mc-services' + '.' + 'eu';document.getElementById('cloakd15ff14d23b491175408c179e001a7b6').innerHTML += ''+addy_textd15ff14d23b491175408c179e001a7b6+'<\/a>'; Disclaimer: This communication expressly or implicitly contains certain forward-looking statements concerning RELIEF THERAPEUTICS Holding AG and its business. You should note that our authors are not investment advisors. The first tranche of EUR 1 million will be advanced concurrent with the execution of the binding term sheet and the second tranche of EUR 1 million upon the successful conclusion of Relief’s phase 2b/3 clinical trial of intravenous RLF-100TM in the treatment of critical COVID-19 patients with respiratory failure. The company is developing a drug candidate RLF-100 for Respiratory Failure in COVID-19 coronavirus patients. Relief Therapeutics (OTC: RLFTF) files SamiAir trademark. NIO Stock: Eaton Vance’s Hexavest buys in, selling Apple and Microsoft, Hexavest, a firm owned 49% by Eaton Vance (EV) has…, On Friday of last week, Novan just hit a new…, Green Energy stocks to watch for this week as Biden takes office, Green energy stocks are going to boom in 2021. var addyd15ff14d23b491175408c179e001a7b6 = 'relief' + '@'; Remember that this is for educational purposes only and since our research can be highly speculative, you should not base your decision solely on this document. Relief Therapeutics and NeuroRx Meet 165 Patient Enrollment Target in Phase 2b/3 Trial of RLF-100™ for Critical COVID-19 with Respiratory Failure 07 December 2020 Correction: NeuroRx and Relief announce initial successful results from expanded access use of RLF-100™ (aviptadil) in patients with Critical COVID-19 … No. By January 2021, Relief and NeuroRx expect to have manufacturing, distribution and logistics capacity in place to deliver sufficient drug quantities to treat 150,000 patients per month with RLF-100. "We look forward to initiating the development of inhaled RLF-100™ in Europe within the coming months for COVID-19 patients using inhaled Aviptadil. You need JavaScript enabled to view it. Sonnet Holdings paid to the Company shares of its common stock that converted into 757,933 shares of listed Sonnet Holdings common stock. Relief focuses primarily on clinical-stage programs based on molecules of natural origin (peptides and proteins) with a history of clinical testing and use in human patients or a strong scientific rationale. Completion of the transaction is subject to approval by stockholders of NeuroRx and Big Rock and other customary closing conditions. Summary Relief Therapeutics has a found a new use for Vasoactive Intestinal Peptide by repackaging it as RLF-100 (Aviptadil) to now fight COVID. Relief also holds a patent issued in the United States and various other countries covering potential formulations of RLF-100TM. Unfortunately, that means its free cash flow fell significantly short of its reported profits. The companies continue to anticipate reporting top-line data from the ongoing randomized, double-blinded, placebo-controlled trial of intravenously-administered RLF-100 … In this administratively-controlled clinical trial, intravenous aviptadil, administered as 3 successive 12 hour infusions of 50/100/150 pmol/kg/hr resulted in a 9-fold advantage in both Under the terms of the agreement, Relief will advance a EUR 2 million convertible secured loan to AdVita. By January 2021, Relief and NeuroRx expect to have manufacturing, distribution and logistics capacity in place to deliver sufficient drug quantities to treat 150,000 patients per month with RLF-100. Since July 2020, severe COVID-19 patients have been treated with RLF-100TM under U.S. FDA Emergency Use Investigational New Drug (IND) authorization and Expanded Access Protocol authorization for the treatment of respiratory failure in COVID-19. Over the course of the past week, RLFTF as gained as much as 25%, and on Monday the company made a major announcement with regards to its partnership agreement with NeuroRx Inc. Article content. On 1 April 2020, Relief divested its subsidiary Relief Therapeutics SA, the focus of which was to develop atexakin alfa, to Sonnet BioTherapeutics, Inc. (“Sonnet Holdings”) through a Share Exchange Agreement (“SEA”) which was executed on 12 August 2019. : +49 (0) 211-529-252-14 Mail: This email address is being protected from spambots. Aviptadil (Vasoactive Intestinal Peptide, VIP), the second product in development, is an abundant biologically active endogenous … The companies continue to anticipate reporting top-line data from the ongoing randomized, double-blinded, placebo-controlled trial of intravenously-administered RLF-100 before the end of 2020. Relief Therapeutics (OTC: RLFTF) is the talk of the town on Wall Street. Shares of Relief Therapeutics rose 6.15% today and will continue to do so in the coming months ahead. Principals, affiliates, staff or authors of Money Midnight may own positions in the securities listed on the site and that we reserve the right to buy or sell without notice at any time. Dr. Jonathan Javitt did not accept his nomination, as announced at the 2020 Ordinary General Meeting, to join the Relief Board of Directors. Our daily stock market updates, stock market Relief Therapeutics’ RLF-100 has been in the market for over 20 years with a history of safe use in humans in multiple human trials for sarcoidosis, … "AdVita's intellectual property around inhaled formulations of Aviptadil and its team’s expertise with Aviptadil will be invaluable as we move forward with the development of the inhaled formulation of RLF-100™ for the treatment of COVID-19-related ARDS, as well as other potential lung disease indications, such as pulmonary Sarcoidosis and Chronic Beryllium Disease," said Jack Weinstein, CFO and Treasurer of Relief. The closing of the transaction is subject to customary closing conditions as well as legal and securities regulatory approvals and is expected to occur in Q2 2021. Under the terms of the transaction, Big Rock will issue to NeuroRx’s current equity holders an aggregate of 50 million shares of Big Rock common stock for their interests in NeuroRx, representing $500 million of equity consideration, assuming a value of $10.00 per common share. Relief Reports Half-Year 2020 Results. Subject to certain conditions, an aggregate of 25 million additional shares of Big Rock common stock will be issued to NeuroRx pre-merger equity holders if, prior to December 31, 2022, (1) RLF-100 receives emergency use authorization by the FDA and (2) the FDA accepts the Company’s filing of its application to approve RLF-100. NeuroRx’s up listing is highly beneficial to both companies. Investor of 12 years and Managing Editor of Money Midnight, a news outlet focused on highly profitable investment ideas and bold underground research. Amongst the AdVita assets being acquired in this transaction, Relief will gain further pending intellectual property rights that may cover RLF-100TM inhaled formulation specifications and the potential application of inhaled Aviptadil in the treatment of Acute Respiratory Distress Syndrome (ARDS) and Checkpoint Inhibitor-induced Pneumonitis (CIP). Relief Announces Implementation of New Share Subscription Facility with Main Shareholder GEM. 2021-01-21 01:21 ET - News Release. Why RLF-100 is bigger than Pfizer and Moderna’s vaccine. We use cookies to ensure that we give you the best experience on our website. Geneva, Switzerland, and Gundelfingen, Germany, January 20, 2021 – RELIEF THERAPEUTICS Holding AG (SIX: RLF, OTCQB: RLFTF) ("Relief"), a biopharmaceutical company with its lead compound RLF-100TM (Aviptadil) in advanced clinical development to treat severe COVID-19 patients, and AdVita Lifescience GmbH ("AdVita"), a Germany-based, privately held pharmaceutical company developing effective products and strategies to improve the treatment and diagnosis of rare lung diseases, today announced the companies have signed a binding term sheet for Relief to acquire all shares of AdVita in exchange for EUR 25 million of Relief common shares, plus possible future contingent milestone payments of up to EUR 20 million. ZURICH — Relief Therapeutics said on Monday it is getting more money from its largest stockholder to lift its cash to 48 million Swiss francs ($52 million) to fund trials of a decades-old medicine it hopes to repurpose against COVID-19. You need JavaScript enabled to view it. In the last twelve months it actually had negative free cash flow, with an outflow of CHF3.5m despite its profit of CHF1.35m, mentioned above. You’ve been successfully subscribed to our newsletter! Its lead drug candidate RLF-100TM (Aviptadil), synthetic vasoactive intestinal peptide (VIP), is being developed in collaboration with NeuroRx, Inc. and is currently being investigated in two placebo-controlled U.S. phase 2b/3 clinical trials in respiratory deficiency due to COVID-19. Money Midnight, our affiliates or the author may or may not have a position in the securities mentioned and reserves the right to buy or sell at any time without notice. var path = 'hr' + 'ef' + '='; RELIEF THERAPEUTICS Holding AG is listed on the SIX Swiss Exchange under the symbol RLF and quoted in the U.S. on OTCQB under the symbol RLFTF. var prefix = 'ma' + 'il' + 'to'; document.getElementById('cloake7685b8770c456e1473f5978e5778bdc').innerHTML = ''; I predict in the future that NeuroRx may acquire Relief Therapeutics since both companies are already integrated with research and development. AdVita Lifescience GmbH was founded in 2019 with the purpose of developing effective products and strategies to improve the therapy and diagnosis of rare lung diseases.